Case 13-2009: A 54-year-old woman with respiratory failure and a cavitary lesion in the lung

New England Journal of Medicine

Volumn 360, Issue 17, 2009, Pages 1770-1779

  Weinblatt, Michael E ^a,c   Abbott, Gerald F ^b,c   Koreishi, Aashiyana F ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; AUTOPSY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL FEATURE; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HISTOPLASMOSIS; HUMAN; LABORATORY TEST; LUNG ABSCESS; LUNG CAVITATION; MALIGNANT NEOPLASTIC DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TOXIC SHOCK SYNDROME; TUBERCULOSIS; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG ANTAGONISM; FATALITY; HYPOTENSION; LUNG; LUNG DISEASE; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SEPTIC SHOCK; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FEMALE; HUMANS; HYPOTENSION; LUNG; LUNG DISEASES; MIDDLE AGED; PNEUMONIA, BACTERIAL; RESPIRATORY INSUFFICIENCY; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65949109283     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0809066     Document Type: Article

References (29)

1. Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968;47:501-520
2. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-2293
3. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-2179
4. Weinblatt ME. Rheumatoid arthritis: more aggressive approach improves outlook. Cleve Clin J Med 2004;71:409-413 (Pubitemid 38821199)
5. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-681
6. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
7. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-1133
8. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-3412
9. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-1764
10. Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997;65:257-260 (Pubitemid 27008930)
11. van der Poll T, Keogh CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997;155:603-608 (Pubitemid 27085808)
12. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-656 (Pubitemid 32525142)
13. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48: 3013-3022 (Pubitemid 37409310)
14. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572
15. Kaneko H, Yamada H, Mizuno S, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999;79:379-386
16. Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 1999;67:3571-3579 (Pubitemid 29291531)
17. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104
18. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-2127 (Pubitemid 36959191)
19. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-1992.
20. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-1265 (Pubitemid 38608568)
21. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-2570
22. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002; 29:1561-1563 (Pubitemid 34755630)
23. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004;50:1959-1966.
24. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-1100 (Pubitemid 32267986)
25. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996;335:547-554
26. Muller MP, Low DE, Green KA, et al. Clinical and epidemiologic features of group A streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003;163:467-472 (Pubitemid 36241025)
27. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007;45:853-862
28. Brown EJ. The molecular basis of streptococcal toxic shock syndrome. N Engl J Med 2004;350:2093-2094 (Pubitemid 38596563)
29. Uthman I, Husari A, Touma Z, Kanj SS. Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept. Rheumatology (Oxford) 2005;44:1200-1201 (Pubitemid 41236036)